Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curt D. Furberg

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptionsCurt D Furberg
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
A new era in hypertension research: discussing the findings of ALLHATCurt D Furberg
Trials|April 13, 2007
Decisions by regulatory agencies: are they evidence-based?Curt D Furberg
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Withdrawal of cerivastatin from the world marketCurt D Furberg, Bertram Pitt
Drug Safety|November 20, 2016
The Harms of Antipsychotic Drugs: Evidence from Key StudiesThomas J Moore, Curt D Furberg
Drug Safety|May 31, 2015
Electronic Health Data for Postmarket Surveillance: A Vision Not RealizedThomas J Moore, Curt D Furberg
Progress in Cardiovascular Diseases|January 10, 2012
Approaches to data analyses of clinical trialsCurt D Furberg, Lawrence M Friedman
Current Hypertension Reports|November 30, 2014
Plasma renin testing to guide antihypertensive therapyAnthony J Viera, Curt D Furberg
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 29, 2003
Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose toleranceHelmut Sinzinger, Harald Kritz, Curt D Furberg
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptionsCurt D Furberg
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
A new era in hypertension research: discussing the findings of ALLHATCurt D Furberg
Trials|April 13, 2007
Decisions by regulatory agencies: are they evidence-based?Curt D Furberg
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Withdrawal of cerivastatin from the world marketCurt D Furberg, Bertram Pitt
Drug Safety|November 20, 2016
The Harms of Antipsychotic Drugs: Evidence from Key StudiesThomas J Moore, Curt D Furberg
Drug Safety|May 31, 2015
Electronic Health Data for Postmarket Surveillance: A Vision Not RealizedThomas J Moore, Curt D Furberg
Progress in Cardiovascular Diseases|January 10, 2012
Approaches to data analyses of clinical trialsCurt D Furberg, Lawrence M Friedman
Current Hypertension Reports|November 30, 2014
Plasma renin testing to guide antihypertensive therapyAnthony J Viera, Curt D Furberg
JAMA Internal Medicine|October 30, 2013
Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008Thomas J Moore, Curt D Furberg
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 29, 2003
Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose toleranceHelmut Sinzinger, Harald Kritz, Curt D Furberg
Pageof 11